KGK Synergize Receives Multi-Site ISO 9001:2000 Certification
KGK Synergize Inc. (KGK) today announced the achievement of registration of its quality management system, ISO 9001:2000 (#CA05/3474), an international standard published by the International Organization for Standardization (ISO).
London, Ont. -- June 1, 2005 - KGK Synergize Inc. (KGK) today announced the achievement of registration of its quality management system, ISO 9001:2000 (#CA05/3474), an international standard published by the International Organization for Standardization (ISO). The accredited registrar, SGS Systems & Services Certification Canada Inc., confirmed KGK's compliance through a formal audit process. The scope of registration is as follows: "The provision of laboratory testing, analytical services, pre-clinical trials and the establishment of protocols and methods for food products, nature, and the nutraceutical and pharmaceutical product industries in accordance with standard good laboratory practices".
"This important accreditation indicates the on-going dedication of our employees to continuously measure and improve the various processes at KGK, in an effort to present our clients with the best possible customer service available at a research organization", states Robert A. Guthrie, V.P., Contract Research Services Division. "KGK is dedicated to reacting to the needs of our consumers and ISO will enable us to monitor, track and record those needs accordingly".
KGK Synergize provides contract research services in the areas of nutraceutical research, analytical chemistry, immunology, toxicology, autoimmune diseases, etc. and clinical trials.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
